Identification of susceptibility biomarkers to new anti-CDK4 drugs in breast cancer
14/06/2017

New progress in treating breast cancer. Prof. Raspé and Roger’s team (WELBIO - IRIBHM – ULB), in collaboration with the Institut Jules Bordet, identified the activating phosphorylation on T172 of CDK4, as the most relevant biomarker to predict the response to palbociclib. The results of this study have been published in EMBO Molecular Medicine.

Breast cancer, the main women cancer (11,000 new cases, 2500 deaths per year in Belgium) is often treated with hormone therapy. It is linked among other metabolic perturbations to a loss of control of the cell cycle, the fundamental process that underlies the multiplication of the cells. Palbociclib, the first specific inhibitor of the kinase CDK4 which plays a crucial role in this control, has just been approved to treat advanced ER+ breast cancer (€ 115,000 per year of treatment).
The diagnostic tools developed by the team should identify patients who are sensitive to this treatment and who will benefit from it. This should facilitate the extension of this drug to other breast cancers. The team is trying to apply the same approach to other cancers lacking efficient treatment.

In a related study supported by Welbio, recently published in Oncogene, the team also identified new kinases and new mechanisms that are responsible for this activating T172 phosphorylation of CDK4.

References: Raspé E. et al., CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib, EMBO Molecular Medicine (2017), DOI 10.15252/emmm.201607084

Colleoni B et al., JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21, Oncogene (2017), doi: 10.1038/onc.2017.7


Last update : 14/6/2017 - Vie privée - Printable version -  © 2019 WELBIO

Home Login